Eli Lilly to acquire Akouos for up to about $610 million and develop gene therapies for hearing loss
marketwatch.com
news
2022-10-18 11:01:23

Eli Lilly and Co. LLY, +0.41% said Tuesday it has entered an agreement to acquire Akouos Inc. AKUS, -5.14%, a company developing a portfolio of viral gene therapies for the treatment of inner ear conditions including hearing loss, for up to $610 million in cash. Under the terms of the deal, Akouos shareholders will receive $12.50 a share in cash, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $3.00 in cash, for a total consideration of up to $15.
